Dianthus Therapeutics (DNTH) AI Stock Analysis

445 Followers

Dianthus Therapeutics

(NASDAQ:DNTH)

Select Model

Rating:51Neutral

Price Target:$86.00▲(3.60% Upside)

Action:reiterated

Date:11/05/26

Overall score reflects a strong, low-debt balance sheet offset by ongoing losses and significant cash burn, with only mixed technical signals. Valuation is a headwind due to the very high P/E and no dividend support.

Positive Factors

Low leverage and capital baseExtremely low leverage limits financial risk from borrowing and preserves flexibility for research, development, and other capital needs. The substantially larger equity base provides Dianthus with a stronger solvency position than many development-stage companies, although it does not yet generate profits.

Negative Factors

No commercial product revenueWithout marketed products, Dianthus lacks a recurring commercial revenue stream to fund operations and validate its business model through customer demand. Financial progress therefore remains dependent on development outcomes and external financing until a therapy can be successfully approved and commercialized.

Dianthus Therapeutics (DNTH) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $4.64B
Dividend Yield: ―
Average Volume (3M): 842.55K
Price to Earnings (P/E): 2767.0
Beta (1Y): 0.85
Revenue Growth: -11.70%
EPS Growth: -14.33%
Country: US
Employees: 92
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Dianthus Therapeutics Business Overview & Revenue Model

Company Description

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended...

How the Company Makes Money

As a clinical-stage biotechnology company, Dianthus Therapeutics does not have product sales and therefore does not generate recurring commercial revenue from marketed therapies. The company primarily funds operations through financing activities typ...

Dianthus Therapeutics Financial Statement Overview

Summary

Financials are mixed: the balance sheet is very strong with minimal leverage and substantially higher equity, but the business remains loss-making with heavy ongoing operating losses and significant negative operating/free cash flow.

Income Statement

24Negative

Balance Sheet

82Very Positive

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.72M	2.04M	6.24M	2.83M	6.42M	1.48M
Gross Profit	2.64M	2.04M	6.24M	2.83M	6.42M	1.48M
EBITDA	-39.40M	-161.91M	-84.56M	-43.20M	-28.33M	-11.09M
Net Income	-39.79M	-162.34M	-84.97M	-43.55M	-28.48M	-13.11M
Balance Sheet
Total Assets	1.28B	530.92M	374.01M	179.41M	83.11M	189.93M
Cash, Cash Equivalents and Short-Term Investments	837.78M	404.30M	275.24M	173.72M	75.49M	176.93M
Total Debt	1.21M	1.39M	1.49M	585.00K	788.00K	0
Total Liabilities	34.82M	37.52M	21.53M	10.54M	9.45M	17.26M
Stockholders Equity	1.24B	493.40M	352.48M	168.87M	73.66M	172.67M
Cash Flow
Free Cash Flow	-175.85M	-129.27M	-78.28M	-36.97M	-29.21M	-60.80M
Operating Cash Flow	-175.15M	-129.06M	-78.18M	-36.86M	-29.07M	-59.53M
Investing Cash Flow	-687.16M	-122.83M	-286.81M	20.25M	-59.82M	43.43M
Financing Cash Flow	862.15M	280.13M	255.62M	133.57M	96.68M	89.60M

Dianthus Therapeutics Technical Analysis

Technical Analysis SentimentNeutral

Last Price83.01

Price Trends

50DMA90.56Negative

100DMA96.39Negative

200DMA85.79Negative

Market Momentum

MACD-1.52Negative

RSI48.49Neutral

STOCH76.53Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Neutral. The current price of 83.01 is above the 20-day moving average (MA) of 79.48, below the 50-day MA of 90.56, and below the 200-day MA of 85.79, indicating a neutral trend. The MACD of -1.52 indicates Negative momentum. The RSI at 48.49 is Neutral, neither overbought nor oversold. The STOCH value of 76.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DNTH.

Dianthus Therapeutics Risk Analysis

Dianthus Therapeutics disclosed 72 risk factors in its most recent earnings report. Dianthus Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Dianthus Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DNTH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VERA	53Neutral	$2.30B	-5.11	-84.13%	―	―	-63.94%
NAMS	52Neutral	$2.50B	-11.05	-31.39%	―	-26.41%	16.12%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DNTH	51Neutral	$4.80B	2767.00	-3.87%	―	-11.70%	-14.33%
VRDN	50Neutral	$3.29B	-7.38	-69.76%	―	-62.83%	-18.22%
OMER	48Neutral	$1.32B	8.94	-109.40%	―	―	―
TVTX	48Neutral	$5.03B	-31.33	-186.46%	―	49.38%	-58.47%

* Healthcare Sector Average

Performance Comparison

DNTH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DNTH	Dianthus Therapeutics, Inc.	83.01	46.73	128.80%
OMER	Omeros Corporation	17.07	10.48	159.03%
TVTX	Travere Therapeutics, Inc.	48.87	16.53	51.11%
VRDN	Viridian Therapeutics, Inc.	28.55	1.11	4.05%
NAMS	Newamsterdam Pharma Company N.V.	18.89	-17.87	-48.61%
VERA	Vera Therapeutics, Inc.	30.14	5.95	24.60%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026

Dianthus Therapeutics AI Stock Analysis